Jun. 23 at 8:13 PM
$SPRO $GSK those happy talk PRs about being leader in AMR mean nothing
It all comes down to $$$$
GSK will improve margins if they use $$$ to buyout the license to avoid milestones
Reverse merger partner -- let's say it is Immunitas -- they don't have anywhere near enough $$$ to go into P3 trials for IMT-009.
Tebi asset sale will take ~6 weeks to close
A reverse merger about 4 months (
$BOLD today pointed to Q4 for its reverse merger to close).
That means Immunitas couldn't access non dilutive Tebi money to kick start IMT-009 trial until end of October 2026.
I doubt Immunitas has enough money to do much of anything -- they likely got 15 million upfront from Boehringer deal to tide them over until they get access to the real $$$$
Timing is TIGHT!!!!!
LFG!!!!!!
